secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001714899-25-000167
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Q2 net loss $124M; FDA priority review for Hunter syndrome BLA, DNL126 accelerated path aligned
--------------------------------------------------------------------------------

- FDA accepted tividenofusp alfa BLA for priority review; PDUFA target action date January 5, 2026.
- FDA agreed CSF HS may be surrogate endpoint for accelerated approval of DNL126 in Sanfilippo syndrome; Phase 1/2 nearing completion.
- Net loss $124.1M for Q2 2025 vs $99.0M in Q2 2024; R&D expenses $102.7M vs $91.4M.
- Cash, cash equivalents, and marketable securities $977.4M as of June 30, 2025.
- Preclinical ATV:Abeta data published in Science; company on track to file 1-2 IND applications in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000167/0001714899-25-000167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000167/dnli-20250811.htm
  HTML page:      https://secwatch.observer/filing/0001714899-25-000167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer